Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 --0%
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
- Tutor Perini launches $400M senior notes offering due 2033
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
